Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumor

Next Previous
Trial Profile

A Phase Ib/II Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumor

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Paclitaxel (Primary) ; Tinengotinib (Primary)
  • Indications Advanced breast cancer; Biliary cancer; Bladder cancer; Cholangiocarcinoma; Gallbladder cancer; Gastric cancer; HER2 negative breast cancer; Male breast cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Thyroid cancer; Triple negative breast cancer
  • Focus Adverse reactions
  • Sponsors TransThera Biosciences

Most Recent Events

  • 12 Jun 2025 Status changed from recruiting to completed.
  • 09 Dec 2024 According to a TransThera Biosciences media release, the company presented Efficacy and Safety Results from this study.
  • 09 Dec 2024 Results(As of September 26, 2024;n=31) published in the TransThera Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top